Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma

Marketwired
Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals Logo
View Comments (0)